Subsequently, the administration of intranasal insulin was found to be safe and have positive effects on neurocognitive performance, memory performance, daily activity, and brain volume during acute, subacute, and chronic phases after ischemic stroke events, both in healthy individuals and in patients with memory impairment such as MCI, AD, PD, and multiple system atrophy. This evidence concerns the gene INS and multiple system atrophy.